Citations 24
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Lee, Stephanie J. , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Bunworasate, Udomsak , Efebera, Yvonne A. , Ferrara, James L.M. , Pidala, Joseph, Howard, Alan , Wu, Juan , Bolaños‐Meade, Javier , Ho, Vincent T. , Alousi, Amin, Weisdorf, Daniel J. , MacMillan, Margaret L. , Weisdorf, Dan , Levine, John E , Holtan, Shernan , DeFor, Todd E. , Panoskaltsis‐Mortari, Angela , Flowers, Mary E.D. , Chen, George L. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Howard, Alan, Alousi, Amin Majid , Blazar, Bruce R. , Lee, Stephanie J , Wood, William A
Blood Advances | August 28, 2018 | Volume: 2 | Issue: 15 | Pages: 1882-1888
10.1182/bloodadvances.2018017343
Key PointsHigh-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
Major-Monfried, Hannah , Renteria, Anne S. , Pawarode, Attaphol , Reddy, Pavan , Ayuk, Francis , Holler, Ernst , Efebera, Yvonne A. , Wölfl, Matthias , Wudhikarn, Kitsada , Ordemann, Rainer, Young, Rachel , Hartwell, Matthew J. , Chaudhry, Mohammed S., Aziz, Mina, Etra, Aaron , Yanik, Gregory A. , Kröger, Nicolaus , Weber, Daniela , Chen, Yi‐Bin , Nakamura, Ryotaro , Rösler, Wolf, Kitko, Carrie L. , Harris, Andrew C. , Kowalyk, Steven, Morales, George , Torres, I.M., Özbek, Umut , Ferrara, James L.M. , Levine, John E. , Kroger, Nicolaus , Kroger, Nicolaus , Levine, John E , Hogan, William J. , Qayed, Muna , Hexner, Elizabeth O. , Shah, Jay Narayan , Pulsipher, Michael A. , Reshef, Ran , Kröger, Nicolaus
Blood | March 15, 2018 | Volume: 131 | Issue: 25 | Pages: 2846-2855
Key Points Biomarker scores generated after 1 week of steroid treatment of GVHD are prognostic. Biomarkers reflect prognosis better than early clinical response to GVHD treatment.
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell, Matthew J. , Özbek, Umut , Holler, Ernst , Renteria, Anne S. , Major-Monfried, Hannah , Reddy, Pavan , Aziz, Mina, Ayuk, Francis , Efebera, Yvonne A. , Bunworasate, Udomsak , Ordemann, Rainer, Wölfl, Matthias , Mielke, Stephan , Pawarode, Attaphol , Chen, Yi‐Bin , Harris, Andrew C. , Jagasia, Madan , Kitko, Carrie L. , Litzow, Mark R. , Morales, George , Nakamura, Ryotaro , Rösler, Wolf, Weber, Daniela , Yanik, Gregory A. , Levine, John E. , Ferrara, James L.M. , Hogan, William J. , Hexner, Elizabeth O. , Qayed, Muna , Mielke, Stephan , Devine, Steven M. , Kröger, Nicolaus , Locatelli, Franco , Reshef, Ran , Wudhikarn, Kitsada , Levine, John E
JCI Insight | February 8, 2017 | Volume: 2 | Issue: 3 | Pages: No page available
BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to the onset of GVHD symptoms. METHODS. Patient blood samples on day 7 after HCT were obtained from a multicenter set of 1,287 patients, and 620 samples were assigned to a training set. We measured the concentrations of 4 GVHD biomarkers (ST2, REG3α, TNFR1, and IL-2Rα) and used them to model 6-month NRM using rigorous cross-validation strategies to identify the best algorithm that defined 2 distinct risk groups. We then applied the final algorithm in an independent test set ( n = 309) and validation set ( n = 358). RESULTS. A 2-biomarker model using ST2 and REG3α concentrations identified patients with a cumulative incidence of 6-month NRM of 28% in the high-risk group and 7% in the low-risk group ( P < 0.001). The algorithm performed equally well in the test set (33% vs. 7%, P < 0.001) and the multicenter validation set (26% vs. 10%, P < 0.001). Sixteen percent, 17%, and 20% of patients were at high risk in the training, test, and validation sets, respectively. GVHD-related mortality was greater in high-risk patients (18% vs. 4%, P < 0.001), as was severe gastrointestinal GVHD (17% vs. 8%, P < 0.001). The same algorithm can be successfully adapted to define 3 distinct risk groups at GVHD onset. CONCLUSION. A biomarker algorithm based on a blood sample taken 7 days after HCT can consistently identify a group of patients at high risk for lethal GVHD and NRM. FUNDING. The National Cancer Institute, American Cancer Society, and the Doris Duke Charitable Foundation.
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Chai, Xiaoyu , Storer, Barry E. , Liu, Hien , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Lukez, Alexander , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Krupski, Christa , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Watanaboonyongcharoen, Phandee , Efebera, Yvonne A. , Ferrara, James L.M. , Weisdorf, Daniel J. , Lee, Stephanie J. , Pidala, Joseph, Chen, George L. , Flowers, Mary E.D. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Panoskaltsis‐Mortari, Angela , Weisdorf, Dan , Levine, John E , Holtan, Shernan , Lee, Stephanie J , Wood, William A
Blood | September 14, 2016 | Volume: 128 | Issue: 19 | Pages: 2350-2358
Key Points Under current treatment approaches, patients with LA GVHD have poor overall and failure-free survival. Levels of AREG are elevated in LA GVHD, and the AREG/EGF ratio is predictive of overall survival and nonrelapse mortality in LA GVHD.